CMMB

Catholic Medical Mission Board Celebrates 110 Years of Service by Equipping Community Health Workers with Life-Saving Tools

Retrieved on: 
Friday, June 3, 2022
Goal, Program, CHAMPS, Thermometer, Health education, Foot, Child, CEO, Partnership, News, CMMB (Catholic Medical Mission Board), Bandage, Travel, Malaria, NGO, Volunteering, Community, Student, GLOBE, Patient, Poverty, Health, COVID-19, World Bicycle Day, CMMB, Parent, Population, MUAC, Mother, Diarrhea, Mobile phone, Medicine, Health insurance, World Bicycle Relief

Catholic Medical Mission Board (CMMB) celebrates 110 years of service by launching a campaign to outfit CMMB-supported community health workers serving in poor, remote communities around the world with bicycles, mobile phones, and life-saving backpacks.

Key Points: 
  • Catholic Medical Mission Board (CMMB) celebrates 110 years of service by launching a campaign to outfit CMMB-supported community health workers serving in poor, remote communities around the world with bicycles, mobile phones, and life-saving backpacks.
  • With over half the worlds population lacking access to quality health services, community health workers are essential to improving the reach of the local health system .
  • These have always been a major impediment to optimized household visitation by community health workers and ultimately impede access to essential health services.
  • Contributions make it possible for CMMB to support community health workers with the tools they need to save more lives.

Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022

Retrieved on: 
Thursday, June 2, 2022
Woman, Raynaud syndrome, ATA, Prognosis, FVC, Fibrosis, EULAR, Time, Research, ELF, Marketing, Cirrhosis, Lung, Survival, Doctor of Philosophy, HIV disease progression rates, R, Systemic scleroderma, Inflammation, Forward-looking statement, Nature, Disease, Primary sclerosing cholangitis, CCL24, Therapy, Scleroderma, Serum, Risk, Patient, Private Securities Litigation Reform Act, Trial of the century, CMMB, Poster, TEL, SEC, Skin, Joint, University of Leeds, Communication, Pharmaceutical industry, Medical imaging, Lead, Rheumatology

TEL AVIV, Israel, June 2, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported that data supporting the role of CCL24 as a therapeutic target for systemic sclerosis (SSc) is being presented in a poster at the EULAR European Congress of Rheumatology this week.1 Chemomab's CCL24-neutralizing antibody, CM-101, is expected to enter a Phase 2 trial in systemic sclerosis later this year.

Key Points: 
  • The findings support the role of CCL24 as a potential therapeutic target, demonstrating elevated serum levels of CCL24 in patients with dcSSc.
  • Adi Mor, PhD, co-founder and Chief Scientific Officer of Chemomab, commented, "We welcome the opportunity to share the growing body of data confirming that CCL24 is a promising therapeutic target for systemic sclerosis at EULAR.
  • These data are timely and informative as we are now finalizing plans for the upcoming Phase 2 trial of our CCL24-neutralizing antibody, CM-101, in systemic sclerosis.
  • The authors conclude that the study data reinforces the rationale for assessing the therapeutic utility of a CCL24-neutralizing antibody in systemic sclerosis clinical trials.

Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Retrieved on: 
Wednesday, May 18, 2022
Inflammation, Primary sclerosing cholangitis, Therapy, CCL24, Cirrhosis, Fibrosis, Webcast, Conference, TEL, CMMB, Pharmaceutical industry

TEL AVIV, Israel, May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .

Key Points: 
  • TEL AVIV, Israel, May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take placeMay 23-26, 2022.
  • Date: Webcast available on demand starting at 7:00am ET May 24 May 26, 2022
    Chemomab is also participating in one-on-one meetings with investors.
  • Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.

Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update

Retrieved on: 
Wednesday, May 4, 2022
Inflammation, Conference, CMMB, Therapy, Cirrhosis, Primary sclerosing cholangitis, Fibrosis, Patient, TEL, ET, CCL24, Pharmaceutical industry, Broadcasting

TEL AVIV, Israel, May 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .

Key Points: 
  • TEL AVIV, Israel, May 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its first quarter 2022 financial results and provide a business update on Thursday, May 12, 2022.
  • Chemomab's management team will review first quarter 2022 performance, discuss recent and upcoming events and conduct a live question-and-answer session.
  • Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.

Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit

Retrieved on: 
Wednesday, March 23, 2022
Therapy, Degenerative disease, Primary sclerosing cholangitis, Doctor of Philosophy, CCL24, CMMB, Inflammation, Pipeline, TEL, Fibrosis, Cirrhosis, Pharmaceutical industry

(Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.

Key Points: 
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.
  • Adi Mor, PhD, co-founder and Chief Scientific Officer of Chemomab, will participate in the panel.
  • Panel: Platforms and Pipelines in a Product: How One Concept Could Have Multiple Applications Across Rare Diseases
    Please reach out to your Cantor Fitzgerald representative to access the Rare Orphan Disease Summit.
  • Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.

CMMB Presents Second Annual Clean Water Campaign for World Water Day, Inspired by College Students to #ACT4Water

Retrieved on: 
Friday, March 18, 2022
Health, Risk, Hunter College, Dublin Housing Action Committee, NEW, Poverty, Woman, Communication, CMMB, Death, CEO, World Water Day, Drinking water, Fordham University, GLOBE, Student, CMMB (Catholic Medical Mission Board), Awareness, Metal Jacket, Water, Volunteering, Medicine

The campaign calls on college students and others to walk 5K, the approximate distance it takes women and children living in low-resource countries around the world to collect water.

Key Points: 
  • The campaign calls on college students and others to walk 5K, the approximate distance it takes women and children living in low-resource countries around the world to collect water.
  • The lack of access to clean water and basic sanitation is one of the most troubling inequalities of our time.
  • Mathew Modine joins college students by advocating for improved access to clean water around the world.
  • Our goal is to think globally and act locally by raising awareness to support communities in need of clean water.

Chemomab Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Retrieved on: 
Thursday, March 10, 2022
Primary sclerosing cholangitis, Cirrhosis, TEL, Inflammation, CMMB, Fibrosis, CCL24, Therapy, Conference, Oppenheimer, Patient, Pharmaceutical industry

TEL AVIV, Israel, March 10, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .

Key Points: 
  • TEL AVIV, Israel, March 10, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings on March 15, 2022, at the 32nd Annual Oppenheimer Healthcare Conference.
  • To request a virtual 1-on-1 meeting with Chemomab management, investors should speak with an Oppenheimer representative.
  • Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update

Retrieved on: 
Wednesday, March 2, 2022
CMMB, Therapy, Conference, Inflammation, TEL, Webcast, Telephone, Pharmaceutical industry, Broadcasting

TEL AVIV, Israel, March 2, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .

Key Points: 
  • TEL AVIV, Israel, March 2, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its fourth quarter and full year 2021 financial results and provide a business update on Wednesday, March 9, 2022.
  • During the conference call, Chemomab's management team will review fourth quarter and full year 2021 performance, discuss recent and upcoming events and conduct a question-and-answer session.
  • Conference Call and Webcast Information:
    Live Webcast at 8:00 am Eastern Time, March 9, 2022
    Click this Webcast link to access the live webcast or replay.

Chemomab Therapeutics to Present at Aegis Virtual Conference

Retrieved on: 
Thursday, February 10, 2022
Inflammation, Conference, Cirrhosis, Therapy, Patient, CMMB, TEL, Primary sclerosing cholangitis, CCL24, Fibrosis, Pharmaceutical industry

(Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will present a company overview at the Aegis Capital Corp.

Key Points: 
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will present a company overview at the Aegis Capital Corp.
  • Virtual Conference on February 24, 2022, at 9:00 am ET.
  • For additional information on accessing the Chemomab presentation, click on Aegis Virtual Conference Calendar .
  • Chemomabis a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.

Catholic Medical Mission Board Releases 2021 Annual Report: “A Call to Mission”

Retrieved on: 
Wednesday, February 9, 2022
Woman, GLOBE, Love, Poverty, Chairperson, Death, Community, Infant, Health, Temperature, Medicine, Mother, CHAMPS, NEW, Annual report, Communication, Heart rate, Volunteering, CMMB (Catholic Medical Mission Board), CMMB, CEO, Child, COVID-19, Hospital

NEW YORK, NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) has released its 2021 Annual Report A Call to Mission, highlighting our unwavering response in addressing maternal and child health inequities through healthcare services and health systems strengthening.

Key Points: 
  • NEW YORK, NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) has released its 2021 Annual Report A Call to Mission, highlighting our unwavering response in addressing maternal and child health inequities through healthcare services and health systems strengthening.
  • In fiscal year 2021, CMMB reached over 1.12 million people around the world with critical health and social services.
  • CMMB distributed over $300 million worth of medicines and medical supplies to 37 health partners for facilities in 22 countries.
  • We selected 'A Call to Mission' as the theme for 2022, our 110th anniversary year.